Search
Now showing items 1-5 of 5
The monoamine oxidase inhibition properties of selected structural analogues of methylene blue
(Elsevier, 2017)
The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals. The central inhibition of MAO-A ...
Methylene blue and its analogues as antidepressant compounds
(Springer, 2017)
Methylene Blue (MB) is considered to have diverse medical applications and is a well-described treatment for methemoglobinemias and ifosfamide-induced encephalopathy. In recent years the focus has shifted to MB as an ...
Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase
(Elsevier, 2012)
Methylene blue (MB) has been shown to act at multiple cellular and molecular targets and as a result
possesses diverse medical applications. Among these is a high potency reversible inhibition of monoamine
oxidase A ...
Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues
(Elsevier, 2010)
Dual action antidepressants have important therapeutic implications. Methylene blue (MB), a charged compound structurally related to tricyclic antidepressants, acts on both monoamine oxidase (MAO) and the nitric oxide ...
Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties
(Elsevier, 2014)
Aims: The phenothiazinium compound, methylene blue (MB), possesses diverse pharmacological actions and is
attracting attention for the treatment of bipolar disorder and Alzheimer's disease. MB acts on both monoamine
oxidase ...